deferiprone has been researched along with calcitriol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cannata Andía, JB; Fernández Martín, JL; González Suárez, I; Naves Díaz, M | 1 |
| De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C | 1 |
| Charoenphandhu, N; Lertsuwan, K; Nammultriputtar, K; Nanthawuttiphan, S; Tannop, N; Teerapornpuntakit, J; Thongbunchoo, J | 1 |
3 other study(ies) available for deferiprone and calcitriol
| Article | Year |
|---|---|
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
Topics: Aluminum; Animals; Bone Neoplasms; Calcitriol; Cattle; Chelating Agents; Culture Media; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Humans; Osteoblasts; Osteocalcin; Osteosarcoma; Pyridones; Secretory Rate; Serum Albumin, Bovine; Tumor Cells, Cultured | 2003 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies; Chelation Therapy; Cytokines; Deferiprone; Deferoxamine; Female; Humans; Intercellular Signaling Peptides and Proteins; Iron Chelating Agents; Male; Osteocalcin; Osteoporosis; Parathyroid Hormone; Pyridones; Risk Factors; Siderophores; Vitamin D | 2006 |
Differential effects of Fe2+ and Fe3+ on osteoblasts and the effects of 1,25(OH)2D3, deferiprone and extracellular calcium on osteoblast viability under iron-overloaded conditions.
Topics: Animals; Biomarkers; Calcification, Physiologic; Calcitriol; Calcium; Cell Cycle Checkpoints; Cell Death; Cell Differentiation; Cell Line; Cell Survival; Deferiprone; Extracellular Space; Iron; Iron Overload; Osteoblasts; Rats; Reactive Oxygen Species | 2020 |